CDT Equity (CDT) Non Operating Income (2022 - 2026)
CDT Equity's (CDT) quarterly Non Operating Income came in at -$407000.0 in Q1 2026, down 131.25% YoY from $1.3 million in Q1 2025, and down 120.57% on a QoQ basis from $2.0 million in Q4 2025.
CDT Equity (CDT) Non Operating Income (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Non Operating Income data on file, last reported at -$407000.0 in Q1 2026.
- Quarterly Non Operating Income fell 131.25% year-over-year to -$407000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 158.61% YoY) and the FY2025 annual result came in at -$319000.0, up 86.61% from the prior year.
- Non Operating Income eased to -$407000.0 in Q1 2026, from $2.0 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3.1 million in Q3 2023 to a low of -$1.8 million in Q4 2024.
- A 5-year average of $139986.3 and a median of -$119000.0 in 2024 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 13382.61% in 2023, down 1641.94% in 2023.
- Tracing CDT's Non Operating Income over 5 years: stood at -$1.4 million in 2022, then soared by 291.41% to $2.7 million in 2023, then sank by 168.66% to -$1.8 million in 2024, then soared by 207.79% to $2.0 million in 2025, then slumped by 120.57% to -$407000.0 in 2026.
- The last three Non Operating Income figures came in at -$407000.0 (Q1 2026), $2.0 million (Q4 2025), and -$85000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | -1.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.64 Mn |
| Mar 31, 2026 | -407,000.00 |
| Dec 31, 2025 | 1.98 Mn |
| Sep 30, 2025 | -85,000.00 |
| Jun 30, 2025 | -57,000.00 |
| Mar 31, 2025 | -176,000.00 |
| Dec 31, 2024 | -1.84 Mn |
| Sep 30, 2024 | -309,000.00 |
| Jun 30, 2024 | -119,000.00 |
| Mar 31, 2024 | -119,000.00 |
| Dec 31, 2023 | 2.67 Mn |
| Sep 30, 2023 | 3.06 Mn |
| Jun 30, 2023 | -845,000.00 |
| Mar 31, 2023 | -157,000.00 |
| Dec 31, 2022 | -1.40 Mn |
| Sep 30, 2022 | -23,000.00 |
| Jun 30, 2022 | 191,585.00 |
| Mar 31, 2022 | 10,182.00 |